Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2017

View Archived Issues

Benitec Biopharma's BB-301 awarded orphan drug status in E.U. for OPMD

EC grants orphan drug designation to PBI-4050 for Alstrom syndrome

FDA, EMA accept Boehringer Ingelheim's BI-695501 for review

FDA grants fast track designation to aTyr Pharma's Resolaris

Global Blood Therapeutics begins enrollment in phase III study of GBT-440

Novel TyroSphere formulation of adapalene for topical acne therapy

Immunomedics presents new data for IMMU-132

Launch of the Coalition for Epidemic Preparedness Innovations

Promising results from final phase III trial of Cimzia in chronic plaque psoriasis

Takeda and Ovid collaborate on TAK-935 for rare pediatric epilepsies

aTyr Pharma provides overview of ongoing projects

NIAID initiates phase I trial of VRC07-523LS

Lilly to acquire CoLucid Pharmaceuticals

Mallinckrodt reaches agreement with FTC over Synacthen Depot

WuXi-MedImmune cleared to conduct phase I studies of WBP-216 in China

Malaria vaccine using genetically engineered Plasmodium falciparum parasites tested in humans

Exelixis discovers new S1P1 and S1P5 receptor agonists

SignalChem Lifesciences describes novel carbonic anhydrase 9, 12 inhibtors

Bioblast Pharma releases results of phase IIa study of trehalose in SCA3 patients

Academia Sinica discloses new glucagon-like peptide 1 modulators

Redx Pharma discovers new compounds promoting interferon alpha production

AstraZeneca presents novel CDK9/cyclin T1 inhibitors

Matrine derivative YF-18 demonstrates therapeutic potential in models of lung cancer

FDA awards rare pediatric disease designation to TXA-127 from Tarix Orphan

HUYA Bioscience enters strategic collaboration with CAS Innovation

Catabasis describes development, structure and plans for CAT-5571

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...